IMV Inc IMVIF

RE:RE:Anyone have access to analyst reports?

[alphaseeking001]

I spoke to them briefly and was told the company was blindsided by the WF downgrade completely.  They felt they had met the guidance criteria given to them directly at the FDA type A meeting last year and hence the confidence moving forward to a type B meeting soon.  They still have 6 women on trial several of whom could potentially still go on to a PR with subsequent scans.  Hence the ORR is a minimum of 21% but could get substantially better even if they got one more PR.  You could easily make the argument that they should have waited to see first... and in hindsight I feel they should have.  It was a perfect storm of a downgrade by the most influential analyst at the same time as the markets were having the worst week in a decade.  Stinks.  I'm holding pat for now as they are obviously moving ahead with an ovarian Type B meeting and have the critical lymphoma and basket results with Keytruda before end of June.  I just don't feel based on their data that the ovarian was a complete mono therapy fail... it clearly is not.  Results with Keytruda will be critical however.  I believe them that they were blindsided as they clearly struck a very positive  tone with their presentations and they also set their options close to $6 in early Feb.  I'm not a fanboy at all and am pretty upset they didn't wait a little longer to get more data and the fact they didn't anticipate this reaction as a possibility makes me question again their decisions but I'm forced to move forward at this point.  Just my 2 cents (which may be worth less than that)